GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » InnoCan Pharma Corp (XCNQ:INNO) » Definitions » 5-Year Dividend Growth Rate

InnoCan Pharma (XCNQ:INNO) 5-Year Dividend Growth Rate : 0.00% (As of Dec. 2023)


View and export this data going back to 2019. Start your Free Trial

What is InnoCan Pharma 5-Year Dividend Growth Rate?

InnoCan Pharma's Dividends per Share for the three months ended in Dec. 2023 was C$0.00.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.

InnoCan Pharma's Dividend Payout Ratio for the three months ended in Dec. 2023 was 0.00. As of today, InnoCan Pharma's Dividend Yield % is 0.00%.

For more information regarding to dividend, please check our Dividend Page.


Competitive Comparison of InnoCan Pharma's 5-Year Dividend Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, InnoCan Pharma's 5-Year Dividend Growth Rate, along with its competitors' market caps and 5-Year Dividend Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InnoCan Pharma's 5-Year Dividend Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, InnoCan Pharma's 5-Year Dividend Growth Rate distribution charts can be found below:

* The bar in red indicates where InnoCan Pharma's 5-Year Dividend Growth Rate falls into.



InnoCan Pharma 5-Year Dividend Growth Rate Calculation

This is the average annual rate that a company has been raising its dividends. The growth rate is calculated with least square regression.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average dividends per share growth rate.


InnoCan Pharma  (XCNQ:INNO) 5-Year Dividend Growth Rate Explanation

1. Dividend Payout Ratio measures the percentage of the company's earnings paid out as dividends.

InnoCan Pharma's Dividend Payout Ratio for the quarter that ended in Dec. 2023 is calculated as

Dividend Payout Ratio=Dividends per Share (Q: Dec. 2023 )/ EPS without NRI (Q: Dec. 2023 )
=0/ -0.005
=N/A

2. Dividend Yield % measures how much a company pays out in dividends each year relative to its share price.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


InnoCan Pharma 5-Year Dividend Growth Rate Related Terms

Thank you for viewing the detailed overview of InnoCan Pharma's 5-Year Dividend Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


InnoCan Pharma (XCNQ:INNO) Business Description

Traded in Other Exchanges
Address
1015, 926 - 5 Avenue SW, Calgary, AB, CAN, T2P 0N7
InnoCan Pharma Corp is a pharmaceutical tech company that focuses on the development of several drug delivery platforms combining cannabidiol with other pharmaceutical ingredients as well as the development and sale of CBD-integrated pharmaceuticals. Geographically, it derives a majority of its revenue from the United States.

InnoCan Pharma (XCNQ:INNO) Headlines

From GuruFocus

President of Innocap, Inc. is in Singapore

By Marketwired Marketwired 05-03-2018

Innocap, Inc.'s Current Activities

By Marketwired Marketwired 05-24-2018

President of Innocap, Inc. is in Singapore

By GlobeNewswire GlobeNewswire 05-03-2018

Innocap, Inc. Year End Message To Shareholders

By PRNewswire PRNewswire 12-14-2020